In this week’s View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in ...

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options ...

In this episode, Clyde W. Yancy, MD, MSc, MACC, and Leslie L. Davis, NP, PhD, FACC, discuss the 2022 AHA/ACC/HFSA Guideline for the Management of HF and where to consider newer treatments with ...

The 2023 European Society of Hypertension (ESH) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both emphasize proper blood pressure (BP) ...

Findings from the PREVUE-VALVE study presented at TCT 2025 shed light on the prevalence of valvular heart disease (VHD) and its subtypes among older Americans, as well as the influence of age, sex, ...

Late-breaking science presented at TCT 2025 addressed immediate PCI guided by instantaneous wave-free ratio (iFR) vs. deferred PCI of nonculprit lesions in acute STEMI patients, as well as management ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

Get coverage of important new developments in cardiology ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

In this week’s View, Dr. Eagle looks at a study comparing the use of aspirin and oral anticoagulants versus anticoagulants alone in the treatment of chronic coronary disease (CCD). He then explores ...

The newest clinical guideline, released May 8 by the ACC and the American Heart Association (AHA), provides the latest evidence-based recommendations for effectively managing individuals diagnosed ...